2-(1-(Dimethylamino)cyclopropyl)ethanol | 774530-46-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-(1-(Dimethylamino)cyclopropyl)ethanol
• 英文别名: 2-[1-(dimethylamino)cyclopropyl]ethanol
• CAS: 774530-46-0
• 化学式: C₇H₁₅NO
• 分子量: 129.2
• InChiKey: MEFSDRUOEADQKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Tyrosine kinase inhibitor compositions, methods of making and methods of use
  申请人：Black Diamond Therapeutics, Inc.

  公开号：US11034672B1

  公开（公告）日：2021-06-15

  The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

  本公开涉及式 I 的新化合物或其药学上可接受的盐或立体异构体 作为受体酪氨酸激酶（RTK）的抑制剂，特别是 ErbB 受体的胞外突变体。本公开还涉及制备这些化合物的方法、包含这些化合物的组合物，以及使用它们治疗哺乳动物（如人类）癌症的方法。
• Nouveaux composés cyclopropaniques 1,1 et 1,2-disubstitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
  申请人：Les Laboratoires Servier

  公开号：EP1170281B1

  公开（公告）日：2005-12-21
• QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE
  申请人：Black Diamond Therapeutics, Inc.

  公开号：EP3856726A1

  公开（公告）日：2021-08-04
• TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE
  申请人：Black Diamond Therapeutics, Inc.

  公开号：US20210163447A1

  公开（公告）日：2021-06-03

  The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).
• [EN] QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE<br/>[FR] DÉRIVÉS DE QUINAZOLINE UTILISÉS EN TANT QU'INHIBITEUR DE TYROSINE KINASE, COMPOSITIONS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION
  申请人：BLACK DIAMOND THERAPEUTICS INC

  公开号：WO2020068867A1

  公开（公告）日：2020-04-02

  The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).